Emerging treatments in headache

European Neurology

Volumn 38, Issue 3, 1997, Pages 167-174

  Diener, Hans Christoph ^a   Gendolla, Astrid ^a   Jüptner, Markus ^a   Kaube, Holger ^a   Limmroth, Volker ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Experimental models; Migraine pathophysiology; Migraine prophylaxis; Treatment of acute attack

Indexed keywords

ERGOTAMINE DERIVATIVE; SEROTONIN AGONIST; SUMATRIPTAN;

ARTICLE; BRAIN BLOOD FLOW; BRAIN STEM; EXPERIMENTAL MODEL; HUMAN; MIGRAINE; NONHUMAN; OCCIPITAL CORTEX; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS;

ANIMALS; BRAIN STEM; CEREBROVASCULAR CIRCULATION; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; MIGRAINE DISORDERS; RECEPTORS, NEUROKININ-1; SEROTONIN AGONISTS; VASOCONSTRICTOR AGENTS;

EID: 0030966304     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000113370     Document Type: Article

References (66)

1. Larsson B, Bille B, Pedersen NL: Genetic influence in headaches: A Swedish twin study. Headache 1995;35:513-519.
2. Joulel A, Bousser M-G, Biouscsc V, Labauge P, Chabriat H, Nibbio A, Maciazek J, Meyer B, Bach M-A. Weissenbach J. Lathrop GM, Tour-nicr-Lasserve E: A gene for familial hemiplegic migraine maps to chromosome 19. Nature Genet 1993;5:40-45.
3. 2+ channel gene CACNL1A4. Cell 1996:87:543-552.
4. Klopstock T, May A, Seibcl P, Papgiannuli E, Diener HC, Reichmann H: Mitochondrial DNA in migraine with aura. Neurology 1996: 46:1735-1738.
5. Leao AAP: Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944:7: 391-396.
6. Olesen J, Larsen B, Laurilzen M: Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981;9:344-352.
7. Olesen J, Friberg L: Xenon-133 SPECT studies in migraine without aura: in Olesen J (ed): Migraine and Other Headaches: The Vascular Mechanisms. London, Raven Press. 1991, pp 237-243.
8. Woods RP, lacoboni M, Mazziotta JC: Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994;331:1689-1692.
9. Weiller C, May A, Limmroth V, Jtiptner M, Kaube H, van Schayck R. Coenen HH. Diener HC: Brain stem activation in spontaneous human migraine attacks. Nature Med 1995:1: 658-660.
10. Diener HC, May A: New aspects of migraine pathophysiology: Lessons learned from positron emission tomography: Editorial review. CurrOpin Neurol 1996;9:199-201.
11. Ferrari MD, James MH, Bates D, Pilgrim AJ, Ashford E, Anderson BA, Nappi G: Oral sumatriptan: Effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994:14:330-338.
12. Blau JN: Clinical characteristics of premonitory symptoms in migraine: in Amcry WK, Wau-quier A (eds): The Prelude to the Migraine Attack. London. Bailliire Tindall. 1986. pp 39-45.
13. Drummond PD, Lance JW: Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol 1983; 13:32-37.
14. Ferrari MD, Saxena PR: On serotonin and migraine: A clinical and pharmacological review. Cephalalgia 1993:13:151-165.
15. Humphrey PPA, Feniuk W: Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sei 1991:12:444-445.
16. Connor HE, Stubbs CM, Feniuk W, Humphrey PP: Effect of sumatriptan, a selective 5-HTI-likc receptor agonist, on pial vessel diameter in anaesthetised cats. J Ccreb Blood Flow Metab 1992:12:514-519.
17. Ray BS, Wollt HG: Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813-856.
18. Markowitz S, Saito K, Moskowitz MA: Neuro-gcnicallv mediated leakage of plasma protein occurs from blood vessels in dura mater, but not brain. J Neurosci 1987;7:4129-4136.
19. Saito K, Markowitz S, Moskowitz MA: Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headaches. Ann Neurol 1988:24:732-737.
20. Buzzi G, Moskowitz MA: The antimigrainc drug, sumatriptan (GR43175). selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202-206.
21. Buzzi G, Sakas DE, Moskowitz MA: Indo-mcthacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989;165:251-258.
22. Shepheard SL, Williamson DJ, Hill RG, Hargreaves RJ: The nonpcptidc neurokinin-1 receptor antagonist. RP 67850. blocks neurogenic plasma extravasation in the dura mater of rats. Br J Pharmacol 1993;110:108-111.
23. Lee WS, Limmroth V, Ayala C, Cutrer FM, Waeber C: Peripheral GABA-A receptors mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 1995:116:1661-1667.
24. Diener HC for the RPR 100893 Migraine Study Group: The substance P antagonist RPR 100893/201 is not effective in human migraine attacks. 6th Headache Res Semin, Copenhagen, November 1995.
25. Gijsman HJ, May A, Wallnöfer A, Jones CR, Diener HC, Ferrari MD for the Boscntan Migraine Study Group: The endothelin antagonist boscntan is not effective in the acute treatment of migraine. Cephalalgia 1995; 15(suppl 14): 267.
26. Goadsby PJ, Gundlach AL: Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: Relevance to migraine. Ann Neurol 1991;29:91-94.
27. Mills A, Graeme RM: Autoradiographic mapping of 3H-sumatriptan binding in eat brains stem and spinal cord: in Olesen J, Moskowitz MA (cds): Experimental Headache Models. Philadelphia, Lippincott-Raven, 1996, pp 89-93.
28. Lambert GA, Lowy AJ, Boers PM, Angus-Lcp-pan H, Zagami AS: The spinal cord processing of input from the superior sagittal sinus: Pathway and modulation by ergot alkaloids. Brain Res 1992:597:321-330.
29. Kaubc H, Hoskin KL, Goadsby PJ: Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Cephalalgia 1993:13(suppl 13):4I.
30. Goadsby PJ, Hoskin KL: Trigeminal neuronal activity is inhibited by intravenous administration of 311C90 in the cat. Cephalalgia 1995; 15: 106.
31. Kaube H, Hoskin KL, Goadsby PJ: Intravenous acetvlsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993; 33:541-544.
32. Raskin NH, Hosobuchi Y, Lamb S: Headache may arise from pertubation of brain. Headache 1987;27:416-420.
33. Wilkinson M, Pfaffenrath V, Schoenen J, Diener HC, Steiner T: Migraine and cluster headache - their management with sumatriptan: A critical rewiew of the current clinical experience. Cephalalgia 1995:15:337-357.
34. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group: A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:332-338.
35. Becker WJ, on behalf of the Study Group: A placebo-controlled, dose-dcfining study of sumatriptan nasal spray in the acute treatment of migraine. Cephalalgia 1995:15(suppl 14):239.
36. Hemandez-Gallego J. on behalf of the Study Group: The efficacy and tolcrability of sumatriptan 10 mg and 20 mg nasal sprays in the acute treatment of migraine. Cephalalgia 1995; 15(suppl 14):240.
37. Göbel H. on behalf of the Study Group: A placebo-controlled. dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Cephalalgia 1995:15(suppl 14):232.
38. Godsby PJ. Hoskin KL: Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)I B/D receptor agonist zol-mitriptan (31IC90): Arc brainstem sites therapeutic target in migraine? Pain 1996:67:355-359.
39. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD: 31IC90, a new central and peripherally acting 5-HTID receptor agonist in the acute oral treatment of migraine: a doubleblind. placebo-controlled, dose-rangc finding study. Neurology 1996:46:522-526.
40. Schoenen J, Klein KB. for the Multinational Oral 3I1C90 and Sumatriptan Comparative Study Group: 311C90 and sumatriptan produce indistinguishable CNS adverse event profiles. Cephalalgia 1996:16:41.
41. Goldstein J, Dahlöf CGH, Diener HC, Olesen J, Schcllens R, Senard JM, Simard D, Steiner TJ, on behalf of the Subcutaneous Alniditan Study Group: Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia 1996; 16:497-502.
42. Cutler NR, Claghorn J, Sramck JJ, Block G, Pancbianco D, Cheng H, Olalt TV, Reines SA: Pilot study of MK-462 in migraine. Cephalalgia 1996;16:113-116.
43. Visser WH, Lines CR, Reines SA and the Rizatriptan Dose-Finding Study Group: Dose-finding studies of rizatriptan (MK 462) in the acute treatment of migraine. Cephalalgia 1996:16: 345.
44. Färkkilä M, Diener HC, Dählöf C, Steiner TJ on behalf of the Elctriptan Steering Committee: A dose-finding study of eletriptan (5-30 mg) for the acute treatment of migraine. Cephalalgia 1996:16:387.
45. Jackson NC, for the Eletriptan Steering Committee: A comparison of oral eletriptan (20-80 mg) and oral sumatriptan (100 mg) in the acute treatment of migraine. Cephalalgia 1996:16: 368.
46. Couch JR, Saper J, Meloche JP. for the North American BMS180048 Study Group: Treatment of migraine with BMS 180048: Response at 2 h. Headache 1996;36:523-530.
47. Visser WH, Jaspers NMWH, de Vricnd RHM. Ferrari MD: Risk factors for headache recurrence after sumatriptan: A study in 366 migraine patients. Cephalalgia 1996;16:264-269.
48. Diener HC, Wilkinson M: Drug-Induced Headache. Berlin. Springer. 1988.
49. Kaube H, May A, Diener HC, PfalTcnrath V: Sumatriptan. BMJ 1994:308:1573.
50. May A, Gijsman HJ, Wallnöfer A, Jones R, Diener HC, Ferrari MD: Endothelin antagonist boscntan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996:67:375-378.
51. Lassen LH, Olesen J: Nitric oxide synthetase (NOS) activation and inhibition in migraine. 7th Headache Research Seminar, Copenhagen, November 1996.
52. Diener HC, Limmroth V: The treatment of migraine. Rev Contemp Pharmacothcr 1994:5: 271-284.
53. Welch KM A: Drug therapy of migraine. N Engl J Med 1993:329:1476-1482.
54. Nappi G, Sandrini G, Savoini G, Cavallini A, de Rysky C. M icicli G: Comparative efficacy of cyclandelatc versus flunarizinc in the prophylactic treatment of migraine. Drugs 1987;33 (suppl 2): 103-109.
55. Mastrosimone F, laccarino C, de Caterina G: Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine. J Med 1992;23:1-11.
56. Schcllenberg R, Bölschc F, Schwarz A, Thom M, Gerber WD, Niederberger U, Soyka D, Wedekind W: Cyclandelate versus propranolol. Clinical and neurophysiological control of therapeutic efficacy in prophylaxis of migraine. Results of a double blind study; in Clifford Rose F (ed): New Adv Headache Res, vol 4. London, Smith-Gordon, 1994, pp 141-148.
57. Diener HC, Föh M, laccarino C, Wessely P, Is-ler HR, Strenge H, Fischer M, Wedekind W, Taneri Z: Cyclandelate in the prophylaxis of migraine: A randomized, parallel, double-blind study in comparison with placebo and propranolol Cephalalgia 1996; 16:441 -447.
58. Hering R, Kurzitzky A: Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992:12:81-84.
59. Jensen R, Brinck T, Olesen J: Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study. Neurology 1994:44: 647-651.
60. Mathew NT, Saper JR, Silberstein SD, Rankin L, Marklcy HG, Solomon S, Rapoport AM. Silber CJ. Deaton RL: Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-286.
61. Silberstein SD: Divalproex sodium in headache: Literature review and clinical guidelines. Headache 1996:36:547-555.
62. Smcets MC, Vcmooy CB, Souverijn JHM, Ferrari MD: Intracellular and plasma magnesium in familar hemiplegic migraine and migraine with and without aura. Cephalalgia 1994:14: 29-32.
63. Ramadan NM, Halvorsen H, Vande-Linde A, Levine SR, Helpern JA, Welch KMA: Low brain magnesium in migraine. Headache 1989; 29:590-593.
64. Pfaffenrath V, Wessely P, Meyer C, lslcr HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Göbel H, Fischer M: Magnesium in the prophylaxis of migraine - a double-blind, placebo-controlled study. Cephalalgia 1996; 16:436-440.
65. Pcikcrt A, Wilimzig C, Köhne-Volland R: Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996:16:257-263.
66. Walach H, Haag G: Homöopathie bei Kopfschmerzen. Schmerz 1996:10:156-162.